Background: Balanced adjustment of the portal vein shunt volume during a transjugular intrahepatic portosystemic shunt (TIPS) is critical for maintaining liver perfusion and decreasing the incidence of liver insufficiency. A stent-graft is proved to be superior to a bare metal stent (BMS) for the construction of a TIPS. However, the clinical results of the combination application of stents and stent-grafts have not been determined. This study aimed to compare the technique of using a combination of stents and stent-grafts with using a single stent-graft to construct a TIPS. Methods: From April 2011 to November 2014, a total of fifty patients were randomly assigned to a stents-combination group (Group I, n = 28) or a stent-graft group (Group...
PURPOSE: To retrospectively evaluate the midterm patency rate of the nitinol (Viatorr, W.L. Gore and...
Introduction. Hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunt (T...
International audienceAn 80% dysfunction rate at 2 years limits the use of transjugular intrahepatic...
Background: Balanced adjustment of the portal vein shunt volume during a transjugular intrahepatic p...
Background & Aims: Transjugular Intrahepatic Portosystemic Shunt (TIPS) is used to control r...
BACKGROUND:Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established treatment...
Transjugular intrahepatic portosystemic stent shunting (TIPSS) appears to be an attractive, nonsurgi...
BackgroundTransjugular intrahepatic portosystemic shunt (TIPS) creation is an established treatment ...
Background & AimsThere is controversy over the ability of transjugular intrahepatic portosystemic sh...
PURPOSEWe aimed to determine the technical feasibility, safety and prognosis of the transjugular int...
Background: Transjugular intrahepatic portosystemic shunt (TIPS) is a standard treatment option for ...
No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/38374/1/1840150334_ftp.pd
ObjectiveTo investigate the clinical effect of Viatorr stent versus double-stent technique in transj...
PURPOSE: In a prospective multicenter study, efficacy and safety of transjugular intrahepatic portos...
Transjugular intrahepatic portosystemic shunt (TIPS) is a non-operative therapeutic option for the m...
PURPOSE: To retrospectively evaluate the midterm patency rate of the nitinol (Viatorr, W.L. Gore and...
Introduction. Hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunt (T...
International audienceAn 80% dysfunction rate at 2 years limits the use of transjugular intrahepatic...
Background: Balanced adjustment of the portal vein shunt volume during a transjugular intrahepatic p...
Background & Aims: Transjugular Intrahepatic Portosystemic Shunt (TIPS) is used to control r...
BACKGROUND:Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established treatment...
Transjugular intrahepatic portosystemic stent shunting (TIPSS) appears to be an attractive, nonsurgi...
BackgroundTransjugular intrahepatic portosystemic shunt (TIPS) creation is an established treatment ...
Background & AimsThere is controversy over the ability of transjugular intrahepatic portosystemic sh...
PURPOSEWe aimed to determine the technical feasibility, safety and prognosis of the transjugular int...
Background: Transjugular intrahepatic portosystemic shunt (TIPS) is a standard treatment option for ...
No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/38374/1/1840150334_ftp.pd
ObjectiveTo investigate the clinical effect of Viatorr stent versus double-stent technique in transj...
PURPOSE: In a prospective multicenter study, efficacy and safety of transjugular intrahepatic portos...
Transjugular intrahepatic portosystemic shunt (TIPS) is a non-operative therapeutic option for the m...
PURPOSE: To retrospectively evaluate the midterm patency rate of the nitinol (Viatorr, W.L. Gore and...
Introduction. Hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunt (T...
International audienceAn 80% dysfunction rate at 2 years limits the use of transjugular intrahepatic...